Brigitte Rack
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. Clin Chem 2024; 70:307-318.
Jan 4, 2024Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Jan 4, 2024Clin Chem 2024; 70:307-318
Fehm Tanja N, Müller Volkmar, Banys-Paluchowski Maggie, Fasching Peter Andreas, Friedl Thomas Wolfram Paul, Hartkopf Andreas D, Huober Jens, Loehberg Christian R, Rack Brigitte, Riethdorf Sabine, Schneeweiss Andreas, Wallwiener Diethelm, Meier-Stiegen Franziska, Krawczyk Natalia, Jaeger Bernadette, Reinhardt Florian, Hoffmann Oliver, Müller Lothar, Wimberger Pauline, Ruckhäberle Eugen, Blohmer Jens-Uwe, Cieslik Jan-Philipp, Franken André, Niederacher Dieter, Neubauer Hans, Pantel Klaus, Janni Wolfgang, DETECT study group
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; 14
Mar 28, 2022MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Mar 28, 2022Cancers (Basel) 2022; 14
Huebner Hanna, Tesch Hans, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Fasching Peter A, Janni Wolfgang, Schneeweiss Andreas, Nabieva Naiba, Jückstock Julia, Häberle Lothar, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Schochter Fabienne, Bekes Inga, Mahner Sven, Rack Brigitte
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
Aug 1, 2021Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Aug 1, 2021JAMA Oncol 2021; 7:1149-1157
Friedl Thomas W P, Tesch Hans, Mahner Sven, Brucker Sara Y, Heinrich Georg, Häberle Lothar, Fasching Peter A, Beckmann Matthias W, Coleman Robert E, Janni Wolfgang, Schneeweiss Andreas, Jückstock Julia, Fehm Tanja, Müller Volkmar, Lichtenegger Werner, Blohmer Jens, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Bekes Inga, Huober Jens, Rack Brigitte
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
Oct 23, 2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
Oct 23, 2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
Apr 6, 2020Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Apr 6, 2020Clin Breast Cancer 2020; 20:439-447
Bekes Inga, Janni Wolfgang, Lato Krisztian, Kiechle Marion, Huober Jens, Dannecker Christian, Forstbauer Helmut, Rack Brigitte, Harbeck Nadia, Friedl Thomas W P, Singer Susanne, Eichler Martin, Fink Visnja
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Schochter F, Friedl T, deGregorio A, Krause S, Huober J, Rack B, Janni W. Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells 2019; 8
Nov 8, 2019Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Nov 8, 2019Cells 2019; 8
Schochter Fabienne, Friedl Thomas W P, deGregorio Amelie, Krause Sabrina, Huober Jens, Rack Brigitte, Janni Wolfgang
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
Cámara R, Singer S, Janni W, Rack B, Widschwendter P, Lato K, Fink V, Deniz M, Friedl T, Schwentner L, Bekes I. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast Cancer Res Treat 2019; 175:627-635.
Mar 21, 2019Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
Mar 21, 2019Breast Cancer Res Treat 2019; 175:627-635
Cámara Rafael J A, Singer Susanne, Janni Wolfgang, Rack Brigitte, Widschwendter Peter, Lato Krisztian, Fink Visnja, Deniz Miriam, Friedl Thomas W P, Schwentner Lukas, Bekes Inga
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast 2018; 44:81-89.
Dec 20, 2018Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Dec 20, 2018Breast 2018; 44:81-89
Deniz Miriam, Andergassen Ullrich, Steidl Julia, Trapp Elisabeth, Fasching Peter A, Häberle Lothar, Beckmann Matthias W, Schneeweiss Andreas, Schrader Iris, Janni Wolfgang, Rack Brigitte, Jueckstock Julia, Kost Bernd, deGregorio Amelie, DeGregorio Nikolaus, Bekes Inga, Widschwendter Peter, Schochter Fabienne, Ernst Kristina, Scholz Christoph, Bauer Emanuel Ca, Aivazova-Fuchs Viktoria, Weissenbacher Tobias, Friedl Thomas Wp
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
May 23, 2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
May 23, 2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Polasik A, Janni W, Huober J, Müller V, Schneeweiss A, Fasching P, Hartkopf A, Rack B, Friedl T, De Gregorio A, Schochter F, Tzschaschel M, Fehm T. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?. Geburtshilfe Frauenheilkd 2017; 77:1291-1298.
Dec 18, 2017Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Dec 18, 2017Geburtshilfe Frauenheilkd 2017; 77:1291-1298
Polasik Arkadius, Janni Wolfgang, Huober Jens, Müller Volkmar, Schneeweiss Andreas, Fasching Peter A, Hartkopf Andreas, Rack Brigitte, Friedl Thomas W P, De Gregorio Amelie, Schochter Fabienne, Tzschaschel Marie, Fehm Tanja
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol 2017; 1:1-12.
Nov 1, 2017Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
Nov 1, 2017JCO Precis Oncol 2017; 1:1-12
De Gregorio Amelie, Janni Wolfgang, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas, Jaeger Bernadette, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Mueller Volkmar, Riethdorf Sabine, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, De Gregorio Nikolaus, Scholz Christoph, Huober Jens, Friedl Thomas W P, Fehm Tanja
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015; 17:129.
Sep 18, 2015The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Sep 18, 2015Breast Cancer Res 2015; 17:129
Widschwendter Peter, Jueckstock Julia, Neugebauer Julia, Trapp Elisabeth, Fasching Peter A, Beckmann Matthias W, Schneeweiss Andreas, Schrader Ines, Rack Brigitte, Janni Wolfgang, Andergassen Ulrich, Kost Bernd, Friedl Thomas Wp, Schwentner Lukas, DeGregorio Nikolaus, Jaeger Bernadette, Schramm Amelie, Bekes Inga, Deniz Miriam, Lato Krisztian, Weissenbacher Tobias, Scholz Christoph
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Schramm A, Janni W, Wallwiener D, Taran F, Hartkopf A, Meier-Stiegen F, Pantel K, Schneeweiss A, Müller V, Alunni-Fabbroni M, Trapp E, Rack B, Huober J, De Gregorio N, Scholz C, Schochter F, Friedl T, Fehm T. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet 2015; 293:271-81.
Sep 9, 2015Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Sep 9, 2015Arch Gynecol Obstet 2015; 293:271-81
Schramm Amelie, Janni Wolfgang, Wallwiener Diethelm, Taran Florin-Andrei, Hartkopf Andreas, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Müller Volkmar, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, Huober Jens, De Gregorio Nikolaus, Scholz Christoph, Schochter Fabienne, Friedl Thomas W P, Fehm Tanja
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
Jul 6, 2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Jul 6, 2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
Sep 25, 2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Sep 25, 2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte
Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 2014; 10:1751-65.
Aug 1, 2014Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Aug 1, 2014Future Oncol 2014; 10:1751-65
Bock Carolin, Rack Brigitte, Huober Jens, Andergassen Ulrich, Jeschke Udo, Doisneau-Sixou Sophie